This prospective observational study will investigate the effect of RoActemra/Actemra (tocilizumab) on fatigue in patients with moderate to severe rheumatoid arthritis who have an inadequate response to disease-modifying antirheumatic drugs or anti-TNF drugs. Data will be collected from patients for 6 months.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01462162?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
